Preview

In Vitro Diagnostics Market Worth $69.1 Billion by 2017

Satisfactory Essays
Open Document
Open Document
415 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
In Vitro Diagnostics Market Worth $69.1 Billion by 2017
The “In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Haematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] – Forecast To 2017” analyzes and studies the major market drivers, restraints, and opportunities in Americas, Europe, Japan, BRIC and Rest of the World.

Browse 178 market data tables and 50 figures spread through 421 pages and in-depth TOC on “In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Haematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] – Forecast To 2017”. http://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html Early buyers will receive 10% customization on reports.

This report studies the global in vitro diagnostics (IVD) market, with forecast to 2017. The IVD market studied in this report has been segmented on the basis of technology, product type, application, end-user, and geography. The global IVD market valued at $49.2 billion in 2012 is primarily driven by rising incidences of chronic and infectious diseases in emerging economies, a rapidly aging population, the rise in point-of-care testing, the rising importance of personalized medicine, ongoing developments in analytical laboratory automation; and finally, the geographical market expansion within emerging countries. However, factors such as stringent regulatory frameworks and a shortage of budget and labor are restraining the growth of the market.

In 2012, the Americas had accounted for the largest share of 41.8% in 2012 of the global In Vitro Diagnostics (IVD) Market. Europe was the second largest-market with the share of 31.0% in 2012. However, the BRIC countries represent the fastest-growing markets due to the economic growth, the rising number of

You May Also Find These Documents Helpful

  • Satisfactory Essays

    mgmt 1101 memo week 3

    • 568 Words
    • 3 Pages

    I recommend that we enter the Indian medical products market to promote our new valuable and innovative dialysis product. This is mainly because India is facing a rapid rise in the number of people who suffer a Chronic Kidney Disease (CKD). There are many modes of operations but I will only consider three of them. Those are Foreign Direct Investment (FDI), Exporting, and Licensing.…

    • 568 Words
    • 3 Pages
    Satisfactory Essays
  • Best Essays

    MIS 535 Course Project

    • 2958 Words
    • 12 Pages

    The company I am choosing to incorporate into this proposal is bioMérieux, who is a world leader in the field of in vitro diagnostics for over 45 years. bioMérieux is present in more than 160 countries through 40 subsidiaries and a large network of distributors. In 2012, revenues reached $1.427 billion with 87% of sales outside of France, where the organization’s corporate headquarters is located. bioMérieux provides diagnostic solutions (reagents, instruments, and software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. The primary use for bioMérieux’ s products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for…

    • 2958 Words
    • 12 Pages
    Best Essays
  • Good Essays

    A dialog between Ventria and its stakeholders offered the options of prioritizing their long list of projects to the one or two with the greatest likelihood of successful commercialization. Analyzing the medical activate proteins to determine which would be which would be a more successful use for the company. Didn’t meet the demonstrated need was there other company’s already proving this particular product and the methods of…

    • 459 Words
    • 2 Pages
    Good Essays
  • Best Essays

    Ldr 531 Week 5

    • 2421 Words
    • 10 Pages

    Plunkett, J. W. (August 19, 2010). Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1975-2009. [Electronic version]. Biotechnology, Drugs & Genetics Industry. Retrieved October 24, 2010 from http://www.plunkettresearchonline.com…

    • 2421 Words
    • 10 Pages
    Best Essays
  • Satisfactory Essays

    Amgen’s Epogen

    • 541 Words
    • 3 Pages

    Hard to obtain for biotech companies because most of these products have already been discovered and isolated.…

    • 541 Words
    • 3 Pages
    Satisfactory Essays
  • Good Essays

    Immune System Case Study

    • 878 Words
    • 4 Pages

    * Rapid tests test for antibodies and not for antigen. Rapid tests are more expensive, have a short shelf life, sites must qualify for Clinical Laboratory Improvement Amendments (CLIA) waiver and ensure training…

    • 878 Words
    • 4 Pages
    Good Essays
  • Powerful Essays

    MicroCHIP Technology- A Renovation in Diabetes Therapy Table of Contents: List of tables and Figures ……………………………………………………………….. 3 Abstract ………………………………………………………………………………… .4 1.0 Introduction…………………………..………………………………………………5 1.1 Back ground of Problem…..…..……………………………………………... 5 1.2 Substitute Technology...…………………...………………………………….8…

    • 5192 Words
    • 21 Pages
    Powerful Essays
  • Best Essays

    There is strong evidence that new technologies offer significant advantages in time management, cost, & availability for the people and the level of training for interpretation in many diagnostic procedure (Lobach, D. F., Low, R., Arbanas,ures,). All these advancements have led to change the way, that health care will be delivered in the future.…

    • 3421 Words
    • 14 Pages
    Best Essays
  • Satisfactory Essays

    Asterand Memo

    • 257 Words
    • 2 Pages

    Asterand clearly did not have an effective quality control system in process prior to accepting its contract with Amgen to supply human tissue samples. Although Asterand is a new supplier to the biopharmaceutical and pharmaceutical industry, it will need to immediately establish quality control methods that will allow them to process orders correctly and deliver the final product to the standards and requirements of the procuring company. This will demonstrate Asterand’s ability to provide consistent and reliable human-tissue samples that meet the rigorous regulatory standards…

    • 257 Words
    • 2 Pages
    Satisfactory Essays
  • Powerful Essays

    Budget Proposal

    • 2559 Words
    • 11 Pages

    The Advanced Technology Program (2006). Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights. Retrieved from http://www.atp.nist.gov/clso/biotech_healthcare.pdf…

    • 2559 Words
    • 11 Pages
    Powerful Essays
  • Good Essays

    Due to increasing competition in the field of medical testing it has become prudent for Laboratorio De Analisis Argentina (LAA) to evaluate its process and identify strengths and weaknesses to improve the operations of their laboratories. An in-depth investigation into day-to-day, step-by-step breakdown of activities has uncovered where, and how LAA can achieve efficient operations.…

    • 1434 Words
    • 6 Pages
    Good Essays
  • Satisfactory Essays

    Biopure case analysis

    • 611 Words
    • 3 Pages

    Deciding whether to go into the veterinary blood market now or not is a critical decision to Biopure right now. To maximize the profits and capture the valuable opportunity, Biopure is recommended to step into the marketplace and be the first to offer Oxyglobin, blood substitute for the animal market. Pioneering the veterinary blood market is expected to generate gross profits of $26.55 miilion to Biopure annually, with a breakeven of 7.5 years to the $200 million in the development cost, without taking into account profits from human sector in the next few years. (Please see Appendix, Figure 1: Oxyglobin Cost/Profits Spreadsheet)…

    • 611 Words
    • 3 Pages
    Satisfactory Essays
  • Best Essays

    Stoiljkovis, V., Trajkovis, J., & Stoiljkovis, B. (2011). Analysis process in a microbiology laboratory. Journal of Medical Biochemistry, 30(4), 346-353.…

    • 4546 Words
    • 15 Pages
    Best Essays
  • Good Essays

    Over the past decade, scientists have made significant advancements in the treatment of certain diseases. Unfortunately, just like any new product, the cost of developing these new technologies and treatments is extremely high. Plus, unlike other technology, heath technology generally doesn't decrease in price over time.…

    • 589 Words
    • 3 Pages
    Good Essays
  • Powerful Essays

    mostly in scientific laboratories will be probably available as a routine tool for doctors, and will be very…

    • 1108 Words
    • 5 Pages
    Powerful Essays